[12] Patent
[11] Patent No.:GC0007587  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126038
Date of the Decision to Grant the Patent:15/Apr/2018

[21] Application No.:GC 2012-21306

[22] Filing Date:19/5/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
19/5/2011
19/10/2011
61/487.789
16/548,957

[72] Inventors:1- Malay Ghosh،2- Laman Alani،3- Francisco Javier Galan،4- Nuria Carreras Perdiguer،5- Daniel A Gamache،6- Onkar N Singh

[73] Owner: Alcon Research,Ltd, ‎6201 South Freeway, IP Legal TB4-8, Fort Worth, ‏76134-2099‏ , Texas, USA

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: A61K 31/335, 47/10, 47/38, 47/40, 9/08; C08B 37/16; C08L 5/16; A61P 27/14; A61K 9/00; B82Y 5/00 (2006.01)

[56] Cited Documents:

-WO 2009/003199 A1 (CYDEX PHARMACEUTICALS INC [US]; PIPKIN JAMES D [US]; ZIMMERER RUPERT O) 31 December 2008
-WO 96/39147 A2 (ALCON LAB INC [US]) 12 December 1996
-WO 01/54687 A1 (ALCON UNIVERSAL LTD [CH]; YANNI JOHN M [US]) 02 August 2001
-WO 2008/015695 A2 (SUN PHARMACEUTICAL IND LTD [IN]; BHOWMICK SUBHAS BALARAM [IN]; LADDHA) 07 February 2008
 
Examiner: PH. Neda J. AlMuallem

[54] HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION
[57] Abstract: The present invention is an ophthalmic composition containing relatively high ‎concentration of olopatadine. The composition is typically an ophthalmic aqueous ‎solution containing relatively high concentrations of olopatadine solubilized within the ‎solution. The composition is preferably capable of providing enhanced relief from ‎symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular ‎allergic conjunctivitis.
No. of claims: 28     No. of figures: 5


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.